Chronic Inflammatory Demyelinating Polyneuropathy Market Expected to rise, 2034 | ICSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Bio

The Chronic Inflammatory Demyelinating Polyneuropathy market growth is driven by factors like increase in the prevalence of Chronic Inflammatory Demyelinating Polyneuropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Inflammatory Demyelinating Polyneuropathy market report [https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Chronic Inflammatory Demyelinating Polyneuropathy market size, share, Chronic Inflammatory Demyelinating Polyneuropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Inflammatory Demyelinating Polyneuropathy market size growth forward.

Some of the key highlights from the Chronic Inflammatory Demyelinating Polyneuropathy Market Insights Report:

*
Several key pharmaceutical companies, including CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others, are developing novel products to improve the Chronic Inflammatory Demyelinating Polyneuropathy treatment outlook.

*
DelveInsight estimates that, in 2023, there were approximately 45,587 diagnosed cases of chronic inflammatory demyelinating polyneuropathy (CIDP) across the 7MM. Of these, the United States represented 66.3% of the cases, the EU4 and the UK accounted for nearly 29.2%, and Japan had 4.5%.

*
The CIDP market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) anticipated from 2024 to 2034. This growth will be driven by the introduction of innovative therapies such as riliprubart, nipocalimab, and batoclimab.

*
According to DelveInsight's analysis, the CIDP market in the 7MM was valued at approximately USD 1,780 million in 2023, and it is projected to expand at a CAGR of 7.2% from 2024 to 2034.

*
Key players in the CIDP market include Octapharma, Pfizer, CSL Behring, and Takeda, which offer approved treatments like HYQVIA in the US and EU, and PRIVIGEN in the US, EU, and Japan.

*
For some patients, treatments may fail to prevent disease progression or reduce frequent relapses, leading to potential disability. Moreover, there is a lack of approved therapies specifically designed for managing CIDP in patients who are prone to relapses. The off-label use of immunoglobulins limits the uptake of approved treatments like HIZENTRA and PRIVIGEN. Additionally, long-term use of corticosteroids or immunosuppressants raises the risk of infections, diabetes, and osteoporosis. In some cases, ineffective treatments fail to prevent relapses or slow disease progression, complicating the management of CIDP and resulting in disability.

*
As per DelveInsight analysis, the Chronic Inflammatory Demyelinating Polyneuropathy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Inflammatory Demyelinating Polyneuropathy Market Landscape [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Inflammatory Demyelinating Polyneuropathy Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological condition marked by inflammation and damage to the myelin sheath, which is the protective covering of the nerves. This damage interferes with the transmission of signals between nerves and muscles, causing progressive weakness and sensory dysfunction.

CIDP can be categorized into typical and atypical forms. The typical form, which is the most common, involves symmetrical polyneuropathy, where both proximal and distal muscles are affected equally, leading to widespread weakness and sensory issues. Symptoms typically develop slowly, though their severity varies from patient to patient, affecting mobility, fine motor abilities, and daily tasks.

Atypical CIDP includes variants such as Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM) or asymmetric CIDP, where nerve damage occurs in specific areas rather than symmetrically. Another form, Distal Acquired Demyelinating Symmetric Neuropathy (DADS), primarily affects the lower limbs and progresses at a slower rate. CIDP can also target only motor or sensory nerves.

The outcome of CIDP is heavily influenced by early diagnosis and appropriate treatment. Many patients experience significant improvements or even remission with immunomodulatory therapies. However, some cases may not respond to treatment, leading to persistent disability, and a small number of patients may have a severe, progressive form of the disease despite ongoing therapy.

Do you know the treatment paradigms for different countries? Download our Chronic Inflammatory Demyelinating Polyneuropathy Market Sample Report [https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Insights

*
DelveInsight estimates that, in 2023, there were approximately 45,587 diagnosed cases of chronic inflammatory demyelinating polyneuropathy (CIDP) across the 7MM. Of these, the United States represented 66.3% of the cases, the EU4 and the UK accounted for nearly 29.2%, and Japan had 4.5%.

*
The CIDP market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) anticipated from 2024 to 2034. This growth will be driven by the introduction of innovative therapies such as riliprubart, nipocalimab, and batoclimab.

*
According to DelveInsight's analysis, the CIDP market in the 7MM was valued at approximately USD 1,780 million in 2023, and it is projected to expand at a CAGR of 7.2% from 2024 to 2034.

*
Key players in the CIDP market include Octapharma, Pfizer, CSL Behring, and Takeda, which offer approved treatments like HYQVIA in the US and EU, and PRIVIGEN in the US, EU, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Inflammatory Demyelinating Polyneuropathy historical patient pools and forecasted Chronic Inflammatory Demyelinating Polyneuropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Inflammatory Demyelinating Polyneuropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Chronic Inflammatory Demyelinating Polyneuropathy Prevalence

*
Age-Specific Chronic Inflammatory Demyelinating Polyneuropathy Prevalence

*
Gender-Specific Chronic Inflammatory Demyelinating Polyneuropathy Prevalence

*
Diagnosed and Treatable Cases of Chronic Inflammatory Demyelinating Polyneuropathy

Visit for more @ Chronic Inflammatory Demyelinating Polyneuropathy Epidemiological Insights [https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease that has gained more attention due to improved diagnostics, greater awareness, and a better understanding of the condition. Treatment usually combines medications and supportive care, aiming to reduce inflammation, modulate the immune system, and enhance motor and sensory functions.

Corticosteroids like prednisone and dexamethasone are commonly used as initial treatments, but they come with significant long-term side effects such as osteoporosis, weight gain, and increased infection risk. These risks often require the addition of steroid-sparing agents, which may not work for all patients.

Plasma exchange has short-term benefits in removing harmful antibodies but is invasive and requires specialized centers. Intravenous immunoglobulin (IVIg) has become the preferred treatment for long-term disease management, though it is costly, time-consuming, and depends on donor plasma, raising concerns about availability.

Approved drugs for CIDP treatment focus on immune modulation, including PANZYGA, an immunoglobulin co-developed by Pfizer and Octapharma, and PRIVIGEN, an immunoglobulin offered by CSL Behring. PRIVIGEN is a room-temperature-stored, ready-to-use IVIg.

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

*
Riliprubart (SAR445088): Sanofi

*
Nipocalimab: Janssen Research and Development

*
Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

*
HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda

*
VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx

*
GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda

Chronic Inflammatory Demyelinating Polyneuropathy Key Companies

*
CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others

For more information, visit Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Chronic Inflammatory Demyelinating Polyneuropathy, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Chronic Inflammatory Demyelinating Polyneuropathy epidemiology in the 7MM

*
Chronic Inflammatory Demyelinating Polyneuropathy marketed and emerging therapies

*
Chronic Inflammatory Demyelinating Polyneuropathy companies

*
Chronic Inflammatory Demyelinating Polyneuropathy market drivers and barriers

Table of Contents:

1 Chronic Inflammatory Demyelinating Polyneuropathy Market Key Comprehensive Insights

2 Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Inflammatory Demyelinating Polyneuropathy

4 Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis Overview at a Glance

5 Executive Summary of Chronic Inflammatory Demyelinating Polyneuropathy

6 Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Market Methodology

7 Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population

8 Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey

9 Chronic Inflammatory Demyelinating Polyneuropathy Treatment Algorithm, Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

11 Chronic Inflammatory Demyelinating Polyneuropathy Marketed Therapies

12 Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies

13 Chronic Inflammatory Demyelinating Polyneuropathy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Inflammatory Demyelinating Polyneuropathy

16 Chronic Inflammatory Demyelinating Polyneuropathy Market Key Opinion Leaders Reviews

18 Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers

19 Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology 2034

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Inflammatory Demyelinating Polyneuropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline 2024

"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy market. A detailed picture of the Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape is provided, which includes the disease overview and Chronic Inflammatory Demyelinating Polyneuropathy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-market-expected-to-rise-2034-icsl-behring-grifols-kedrion-biopharma-nihon-pharmaceutical-lfb-teijin-pharma-octapharma-shire-takeda-ucb-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.